Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05275868 · ClinicalTrials.gov registry record · Phase 1
Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT05275868: Clinical Trial Phase 1 study, sponsored by Novartis Pharmaceuticals.
NCT05275868 is a Phase 1 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 41 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05275868, a Phase 1 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
Study of MGY825 single agent in adult patients with advanced non-small cell lung cancer.
Primary Outcome
Assessment of safety of study drug as a single agent
Interventions
- DRUG MGY825
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2022-10-05 |
| Est. Completion | 2025-10-13 |
| Phase | Phase 1 |
Why NCT05275868 stopped before completion
NCT05275868 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 1 intervention - of which MGY825 is the first listed.
NCT05275868 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05275868 about?
NCT05275868 is a clinical study titled "Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer". Study of MGY825 single agent in adult patients with advanced non-small cell lung cancer.
What is the current status of trial NCT05275868?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2022-10-05. Estimated completion is 2025-10-13.
What interventions are being tested in trial NCT05275868?
The interventions under investigation include: MGY825 (DRUG).
Who is sponsoring clinical trial NCT05275868?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05275868's enrollment target sits among peer trials
41 1125th of 2000 higher than 871 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI